Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
54
Recruiting, any sponsor type, condition "alopecia areata"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed199
54 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07772492 · 300 participants (planned) · Start Aug 24, 2026 · Primary completion Mar 2032
Drug: Upadacitinib; Placebo · For: Severe Alopecia Areata
Sites: Los Angeles, California; Miami, Florida; Meridian, Idaho · 22 sites in all
- Phase 2/3 Efficacy and Safety of PP405 in Adult MalesPivotal-lookingRecruiting
Pelage Pharmaceuticals, Inc.Industry
NCT07819435 · 600 participants (planned) · Start Sep 21, 2026 · Primary completion Dec 2027
Drug: PP405 0.05% Topical Gel; Vehicle Topical Gel · For: Androgenetic Alopecia
Sites: Birmingham, Alabama; Fort Smith, Arkansas; Hot Springs, Arkansas · 63 sites in all
Sohag UniversityAcademic, hospital or other
NCT07947992 · 60 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 1, 2027
Drug: Metformin 30% Topical Lotion; Minoxidil 5 % Topical Spray · For: Alopecia Areata(AA)
Sites: Sohag, Egypt
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06873945 · 674 participants (planned) · Start Apr 1, 2025 · Primary completion Mar 19, 2028
Drug: Ritlecitinib 100 mg; Ritlecitinib 50 mg and 2 more · For: Alopecia Areata
Sites: Birmingham, Alabama; Hot Springs, Arkansas; Brea, California · 148 sites in all
- A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07029828 · 140 participants (planned) · Start Sep 10, 2025 · Primary completion Jun 26, 2030
Drug: Ritlecitinib higher dose; Ritlecitinib lower dose · For: Severe Alopecia Areata
Sites: Irvine, California; Santa Ana, California; Aurora, Colorado · 69 sites in all
- Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic AlopeciaPivotal-lookingRecruiting
Pelage Pharmaceuticals, Inc.Industry
NCT07907783 · 200 participants (planned) · Start Nov 10, 2026 · Primary completion Sep 2027
Drug: PP405 0.05% Topical Gel; Vehicle Topical Gel · For: Androgenetic Alopecia
Sites: Hot Springs, Arkansas; Atlanta, Georgia; New York, New York · 6 sites in all
- SCALp Cooling for pReventing aLopecia With nEw anTibody-drug ConjugatesPivotal-lookingRecruiting
Jules Bordet InstituteAcademic, hospital or other
NCT07474558 · 102 participants (planned) · Start Oct 23, 2026 · Primary completion Jan 15, 2030
Drug: Antibody-Drug Conjugates · For: Advanced or Metastatic Solid Tumour; Antibody-Drug Conjugate; Alopecia
Sites: Anderlecht, Belgium; Mons, Belgium; Namur, Belgium
- Comparative Effectiveness of Intralesional Injection of Triamcinolone Acetonide vs. Microneedling With Local Application of Triamcinolone Acetonide in the Treatment of Alopecia AreataPivotal-lookingRecruiting
Dow University of Health SciencesAcademic, hospital or other
NCT07926711 · 276 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 2026
Drug: Triamcinolone acetonide · For: Alopecia Areata
Sites: Karachi, Pakistan
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05398809 · 70 participants (planned) · Start Jan 18, 2023 · Primary completion Dec 1, 2027
Drug: Ruxolitinib · For: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced); Alopecia Areata
Sites: Bethesda, Maryland
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05723198 · 595 participants (planned) · Start Feb 27, 2023 · Primary completion Mar 2028
Drug: Baricitinib; Placebo · For: Areata Alopecia; Alopecia; Hypotrichosis and 3 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Encinitas, California · 127 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07533006 · 65 participants (planned) · Start Apr 14, 2026 · Primary completion Jun 2027
Drug: LY4005130; Placebo · For: Alopecia Areata
Sites: Fremont, California; Northridge, California; Santa Clarita, California · 30 sites in all
- Tirzepatide for Treatment of CCCARecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT07734870 · 20 participants (planned) · Start Sep 15, 2026 · Primary completion May 25, 2028
Drug: Tirzepatide · For: Central Centrifugal Cicatricial Alopecia (CCCA)
Sites: Baltimore, Maryland; Columbia, Maryland
- Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia AreataPivotal-lookingRecruiting
Sun Pharma Japan LimitedIndustry
NCT07617597 · 78 participants (planned) · Start Jun 19, 2026 · Primary completion Feb 2028
Drug: Deuruxolitinib; Placebo · For: Alopecia Areata
Sites: Asahikawa, Japan; Bunkyō City, Japan; Ebina, Japan · 18 sites in all
- Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic AlopeciaPivotal-lookingRecruiting
Absci Pty Ltd.Industry
NCT07317544 · 227 participants (planned) · Start Dec 3, 2025 · Primary completion Jul 2028
Drug: SAD IV Dose 1 - 150mg ABS201 IV Single Dose; Placebo IV and 2 more · For: Androgenetic Alopecia (AGA); Healthy Volunteers - Male and Female
Sites: Sydney, Australia; Brisbane, Australia; Melbourne, Australia · 5 sites in all
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07733765 · 336 participants (planned) · Start Jul 30, 2026 · Primary completion Apr 26, 2028
Drug: Ritlecitinib 100 mg; Ritlecitinib 50 mg · For: Alopecia Areata
Sites: Encinitas, California; Miami, Florida; Skokie, Illinois · 38 sites in all
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07762443 · 24 participants (planned) · Start Sep 22, 2026 · Primary completion Dec 30, 2027
Drug: VC005 tablets · For: Alopecia Areata
Sites: Beijing, China
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06012240 · 1,500 participants (planned) · Start Oct 11, 2023 · Primary completion Apr 2030
Drug: Upadacitinib; Placebo · For: Alopecia Areata
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 272 sites in all
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT07242638 · 56 participants (planned) · Start Jan 12, 2026 · Primary completion Feb 23, 2029
Drug: Abrocitinib · For: Atopic Dermatitis; Alopecia Areata
Sites: New York, New York
- A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic AlopeciaPivotal-lookingRecruiting
Olix Pharmaceuticals, Inc.Industry
NCT07327359 · 158 participants (planned) · Start Dec 4, 2025 · Primary completion Sep 2027
Drug: OLX72021; OLX72021 and 2 more · For: Androgenetic Alopecia (AGA)
Sites: Botany, Australia; Kogarah, Australia; Newcastle, Australia · 8 sites in all
HCW BiologicsIndustry
NCT07049328 · 30 participants (planned) · Start Aug 16, 2025 · Primary completion Jul 16, 2027
Drug: HCW9302, an IL-2 fusion protein · For: Alopecia Areata(AA)
Sites: Tampa, Florida; Indianapolis, Indiana; Columbus, Ohio
Istanbul Training and Research HospitalGovernment (non-federal)
NCT07803874 · 40 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 2026
Drug: Triamcinolone Acetonide · For: Alopecia Areata
Sites: Istanbul, Turkey (Türkiye)
- A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic AlopeciaPivotal-lookingRecruiting
Chong Kun Dang PharmaceuticalIndustry
NCT06916793 · 288 participants (planned) · Start Apr 8, 2025 · Primary completion Sep 30, 2027
Drug: CKD-843 dose#1; CKD-843 dose#2 and 3 more · For: Androgenetic Alopecia
Sites: Seoul, South Korea
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT05866562 · 76 participants (planned) · Start Jul 11, 2024 · Primary completion Mar 31, 2029
Drug: Dupilumab; Placebo · For: Alopecia Areata
Sites: Irvine, California; San Diego, California; Chicago, Illinois · 5 sites in all
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT05928169 · 1,000 participants (planned) · Start May 1, 2023 · Primary completion Apr 30, 2032
Drug: Topical and systemic drugs · For: Atopic Dermatitis; Psoriasis; Lichen Planus and 5 more
Sites: Kiel, Germany
- Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia AreataPivotal-lookingRecruiting
Jiangsu vcare pharmaceutical technology co., LTDIndustry
NCT07749716 · 120 participants (planned) · Start Aug 18, 2026 · Primary completion Dec 30, 2028
Drug: Drug: VC005 tablets; VC005 tablets and 1 more · For: Alopecia Areata
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.